Search Results 301-310 of 17757 for Biliary obstruction to assess
Recently, the EDII was developed and validated to assess inflammatory potential of diet based on the Food Frequency Questionnaire (FFQ) (13). Here we propose to ...
... assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the ...
The finding suggests that a simple blood test may help healthcare professionals monitor people for early signs of PBC. Basic research related to PBC and ...
The purpose of this study is to evaluate how well gemcitabine, cisplatin, and nab-paclitaxel work before surgery in treating participants with high-risk bile ...
This can lead to a bowel blockage, called obstruction. ... Assessing morbidity, mortality, and survival ... Community Health Needs Assessment · Financial ...
Researchers at Mayo Clinic also advanced the use of the fluorescence in situ hybridization, also called FISH, test in the diagnosis of bile duct cancer in ...
It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers.
Bilirubin < 3.0 mg/dl (in the absence of obstruction or pre-existing disease of the biliary tract; e.g., primary sclerosing cholangitis). Patients ...
... Bile duct injury, Bile duct cyst, Small bowel cancer, Bile duct stricture, Gallbladder polyp, Bile duct stone, IPMN, Biliary obstruction, Retroperitoneal ...
Study To Evaluate The Safety, Tolerability, PDs, And Efficacy Of CNP-104 In Subjects With Primary Biliary Cholangitis · Share · Facebook · Twitter.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.